Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Oliver RiestererGabriela Studer

Abstract

Preclinical data suggest that cetuximab should be continued after end of concurrent radiotherapy+cetuximab due to its efficacy against residual tumor cells in the irradiated tumor bed. Based on this concept the phase II add-on cetuximab (AOC) study was designed. Altogether 63 patients with advanced head and neck cancer were treated with radiochemotherapy (70 Gy, cisplatin 40 mg/m2 weekly) in combination with concurrent cetuximab (loading dose 400 mg/m2, then 250 mg/m2 weekly). Thereafter patients were randomized to cetuximab consolidation (500 mg/m2 biweekly × 6) or no further treatment. The primary endpoint was the 2-year locoregional control (LRC) rate. As translational research endpoints serum markers were analyzed before and during treatment and CT-based quantitative image analysis (radiomics) was performed. Median follow-up was 24 months. The 2-year LRC rates were 67.9% and 67.7% in the treatment arms with and without consolidation cetuximab, respectively. Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p ≤ 0.05). A radiomics model consisting of two radiomics features could be built showing that higher entropy an...Continue Reading

References

Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J AdelsteinArlene A Forastiere
Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pia HugueninChristoph Glanzmann
Feb 9, 2005·International Journal of Immunopathology and Pharmacology·P SommaS Staibano
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Jan 24, 2007·International Journal of Radiation Oncology, Biology, Physics·Luka MilasK Kian Ang
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Aug 22, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Oliver RiestererLuka Milas
Nov 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Annette M LimQuynh-Thu Le
Mar 3, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Quynh-Thu LeDanny Rischin
Aug 29, 2012·Molecular Cancer Therapeutics·Atul BediRajani Ravi
Oct 19, 2013·International Journal of Cancer. Journal International Du Cancer·Yusuke NakadateFumiaki Koizumi
Jun 4, 2014·Nature Communications·Hugo J W L AertsPhilippe Lambin
Aug 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ann Marie EgloffArlene A Forastiere
Aug 27, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Kian AngRita S Axelrod
Nov 29, 2016·Physics in Medicine and Biology·M BogowiczS Tanadini-Lang
Aug 16, 2017·International Journal of Radiation Oncology, Biology, Physics·Marta BogowiczStephanie Tanadini-Lang
Nov 11, 2017·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Marta BogowiczPhilippe Lambin
Feb 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R MesíaR López-López

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nature Reviews. Drug Discovery
Joanne GrahamPeter Kirkpatrick
The New England Journal of Medicine
Orlando Guntinas-Lichius
Indian Journal of Cancer
P M ParikhA Vora
© 2022 Meta ULC. All rights reserved